Phase 2 N=12 H-22411: BOTOX® for Peyronie's Disease
Peyronie's Disease
Primary: Average Percent Change of Penile Curvature in Degrees — -21.73; 2.429 percent change — p=0.5154
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,459 Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
Priapism · Anemia, Sickle Cell
Primary: Enumeration of the Prevalence of Priapism in Males With Sickle Cell Anemia and Sickle Beta Zero Thalassemia. — 18; 58; 160; 189 participants
N/A N=110 Penile Length Restoration in Men With Diabetes Mellitus, Type II
Diabetes Mellitus, Type 2 · Penile Diseases
Primary: Penile Length Change Between Baseline and Month 6 — 0; 0.5; 0.5; 0.8 Median change from baseline (cm)
N/A N=110 Efficacy of Penile Traction Therapy Using a Novel Device
Penile Diseases
Primary: Adverse Events at Baseline — 2; 2; 1; 7 percentage of participants
N/A N=82 Penile Length Maintenance Post-Prostatectomy
Prostate Cancer · Penile Diseases
Primary: Change in Penile Length — 0.3; 1.6 centimeters
N/A N=12 Erectile Rating During the Treatment of Rectal Cancers Localized
Rectal Cancer Stage I
Primary: Proportion of Patients With Erectile Dysfunction Induced by Medical and Surgical Treatment of Rectal Cancer — 0 Participants
Phase 3 N=347 A Study of AA4500 in Men With Peyronie's Disease
Peyronie's Disease
Primary: Percentage Change From Baseline in Penile Curvature — -34.4 percentage of curvature change
Phase 3 N=417 Study of AA4500 in the Treatment of Peyronie's Disease
Peyronie's Disease
Primary: Percentage Change From Baseline in Penile Curvature — -37.6; -21.3 percentage of curvature change — p=0.0005
Phase 3 N=415 Study of AA4500 in the Treatment of Peyronie's Disease
Peyronie's Disease
Primary: Percentage Change From Baseline in Penile Curvature — -30.5; -15.2 percentage of curvature change — p=.0059
N/A N=40 Evaluation of the Coloplast Titan® IPP for Maintaining Penile Length While Treating Erectile Dysfunction (ED)
Erectile Dysfunction
Primary: The Study's Primary Objective Will Assess the Change in Penile Length. — 1.14; 0.99; 1.04; 0.94 cm
N/A N=258 Dorsal Penile Nerve Block for Rigid Cystoscopy in Men
Pain
Primary: Visual Analog Scale (VAS) for Pain — 6; 4; 4 units on a scale
N/A N=98,832 Identification of Underlying Conditions in Men Prescribed a PDE5 Inhibitor
Erectile Dysfunction · Cardiovascular Diseases · Male Urogenital Diseases
Primary: Percentage of Participants With Underlying Condition Until Day -1 of the Index PDE5i Prescription — 70.23; 55.73 Percentage of participants — p=<0.001
Phase 3 N=52 Evaluate Use of Caudal Nerve Blocks in Adult Penile Prosthesis
Malignant Neoplasms of Male Genital Organs
Primary: Post-Operative Pain Medication Usage in Post Anesthesia Care Unit (PACU) — 13.0208; 15.1786 mg
N/A N=20 Penile Nerve Stimulation for Treatment of Delayed Ejaculation
Delayed Ejaculation
Primary: International Index of Erectile Function (IIEF) Scale Score — 7.5; 9.7 score on a scale
Phase 2 N=147 The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease
Peyronie's Disease
Primary: Change From Baseline in Penile Curvature — -29.7; -11.0 Percent change from baseline — p=0.001
Phase 4 N=24 Testosterone for Peripheral Vascular Disease
Hypogonadism · Peripheral Vascular Disease · Type 2 Diabetes
Primary: Change in Arterial Stiffness — 15.02; 15.08; 14.08; 16.12 index β
N/A N=20 MED3000 Topical Gel for On-Demand Treatment of Post-Radical Prostatectomy Erectile Dysfunction
Erectile Dysfunction Following Radical Prostatectomy
Primary: Whether the Erectile Function Domain of the International Index of Erectile Function Mean Change From Baseline Met or Exceeded the Minimally Clinically Important…
Phase 2 N=13 Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia
Sickle Cell Disease · Priapism
Primary: Greater Than or Equal to a 50% Reduction in Priapic Episodes — 3; 3 Number of participants — p=1
Phase 3 N=189 A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease
Peyronie's Disease
Primary: Percentage Change From Baseline in Penile Curvature — -36.3 percentage of curvature change
Phase 2 N=30 Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis
Penile Cancer
Primary: Number of Participants With Pathologic Complete Remission (pCR) — 3 participants
Phase 2 N=61 Safety and Efficacy of Autologous Platelet-Rich Plasma for Erectile Dysfunction.
Erectile Dysfunction
Primary: Number of Participants Achieving MCID in IIEF-EF. — 14; 15; 10; 13 Participants
Phase 2 N=135 Vessel Sparing Prostate Radiation Therapy
Cancer of the PROSTATE
Primary: The Percentage of Patients Able to be Sexually Active With or Without the Use of Aids — 88 percentage of patients
Phase 4 N=284 Penicillin Allergy Testing in STD Clinics
Penicillin Allergy
Primary: Number of Respondents Who Responded YES to Any Question Defining High Risk Penicillin Allergy Using Questionnaire Developed by the Study — 36; 36 Participants
Phase 3 N=618 Treatment of Erectile Dysfunction I
Erectile Dysfunction
Primary: Change in Erectile Function Domain Assessed by International Index of Erectile Function (IIEF), Baseline to Final Visit/Week 12, mITT (Modified Intent-to-Treat), LOCF…
Phase 1 N=59 Shockwave Therapy and Platelet Rich Plasma for the Treatment of Erectile Dysfunction
Erectile Dysfunction
Primary: Number of Participants With Treatment Emergent Serious Adverse Events (TE-SAEs) During the Study Period. — 0; 0 Participants
N/A N=16 Surface Stimulation for Female Sexual Dysfunction
Female Sexual Dysfunction
Primary: 6 Weeks - Total FSFI Score — 26.0; 17.4 score on a scale — p=0.109
Phase 3 N=9 Novel Topical Therapies for the Treatment of Genital Pain
Female Genital Diseases
Primary: Reduction in Daily Genital Pain. — 2.4; 2.92; 3.42; 2.77 units on a scale — p=0.30
Phase 2 N=14 Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation Therapy for Prostate Cancer
Male Erectile Disorder · Prostate Adenocarcinoma · Erectile Dysfunction, CTCAE
Primary: Change in International Index of Erectile Function (IIEF) Scores — 0; 0; 0 Participants
Phase 2 N=5 Clostridium Histolyticum Collagenase Injection for Urethral Disease
Urethral Stricture
Primary: Number of Subjects With Complication After Treatment — 0 Participants
N/A N=1,457 PROPPER Prospective Registry of Outcomes With Penile Prosthesis
Erectile Dysfunction · Impotence
Primary: Number of Participants With Penile Prosthesis Overall Subject Satisfaction — 34; 34; 0; 0 Participants